Pages that link to "Q80843544"
Jump to navigation
Jump to search
The following pages link to Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting (Q80843544):
Displaying 50 items.
- Regulation of glucose homeostasis by GLP-1 (Q24563430) (← links)
- Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease (Q26784211) (← links)
- Glycemic variability and glycemic control in the acutely ill cardiac patient (Q26821994) (← links)
- Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists (Q26823085) (← links)
- Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies (Q26866958) (← links)
- Incretins and the intensivist: what are they and what does an intensivist need to know about them? (Q26995464) (← links)
- Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system (Q27010014) (← links)
- Glucagon orchestrates stress-induced hyperglycaemia (Q28068879) (← links)
- Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association (Q28076059) (← links)
- Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials (Q28081569) (← links)
- GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans (Q30407530) (← links)
- GLP-1 (7-36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles (Q30411123) (← links)
- Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists (Q33521451) (← links)
- The incretin system and cardiometabolic disease (Q33776092) (← links)
- The potential role of incretin therapy in the hospital setting (Q33792390) (← links)
- Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease (Q33939256) (← links)
- Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies (Q33949425) (← links)
- Cardiovascular effects of incretin therapy in diabetes care (Q34171759) (← links)
- Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study (Q34283308) (← links)
- Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus (Q34374314) (← links)
- Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies (Q34620430) (← links)
- Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. (Q34653078) (← links)
- Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based Therapies (Q34716791) (← links)
- Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes (Q34771795) (← links)
- Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study (Q35174285) (← links)
- Bench-to-bedside review: The gut as an endocrine organ in the critically ill (Q35559137) (← links)
- The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill (Q35559222) (← links)
- Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart (Q35670896) (← links)
- Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial (Q35759370) (← links)
- Role of CABG in the management of obstructive coronary arterial disease in patients with diabetes mellitus (Q36092782) (← links)
- Coronary artery disease and diabetes mellitus (Q36355228) (← links)
- The Cardiovascular Effects of GLP‐1 Receptor Agonists (Q36368998) (← links)
- Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts (Q36895565) (← links)
- Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity (Q36906298) (← links)
- Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated Cardiomyopathy (Q36939647) (← links)
- Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment (Q36942108) (← links)
- Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection (Q36980756) (← links)
- Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering (Q37082698) (← links)
- Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study (Q37125983) (← links)
- Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides (Q37212333) (← links)
- Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. (Q37274296) (← links)
- Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. (Q37316259) (← links)
- Incretins in the ICU: is insulin on its way out? (Q37360261) (← links)
- Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? (Q37395298) (← links)
- GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects (Q37396567) (← links)
- Therapeutic targets to reduce cardiovascular disease in type 2 diabetes (Q37464731) (← links)
- Glucagon-like peptide-1 and myocardial protection: more than glycemic control. (Q37487946) (← links)
- Glucagon-Like Peptide 1—A Cardiologic Dimension (Q37777868) (← links)
- Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based Therapies (Q37824904) (← links)
- The potential role of glucagon-like peptide-1 or its analogues in enhancing glycaemic control in critically ill adult patients (Q37825601) (← links)